> Mylan has decided against selling its specialty pharmaceutical division, Dey, after a review of strategic alternatives for the subsidiary. Report
> U.S. life scientists are feeling somewhat flush these days. The Scientists' fifth annual salary survey shows that median compensation in the U.S. jumped 15 percent since 2006, rising from $74,000 to $85,000. Salary report
> A new study shows that women and men with depression respond differently to treatment with SSRI drugs, with women being 33 percent more likely to achieve full remission. Report
> Novartis said its experimental drug RAD001 has been granted priority review by the U.S. Food and Drug Administration for approval as treatment for advanced kidney cancer, paving the way for possible approval early next year. Report
> The market for hepatitis C treatments in China will grow to $150 million by 2012, according to Decision Resources. Report
> Salix Pharmaceuticals said it filed a lawsuit against Novel Laboratories Inc. over its colonoscopy preparation tablet, OsmoPrep. Report
> Australian researchers are starting a three-year trial to test Eli Lilly's Evista, the osteoporosis med, as a treatment for schizophrenia. Report
> Biodel reported positive results from two pivotal Phase III clinical trials comparing VIAject to Eli Lilly's Humulin R for patients with Type 1 and Type 2 diabetes. But despite the positive spin, investors fled after learning that one of the Phase III trials reportedly would have failed if researchers had not excluded results from India and that 24 patients had dropped out of the trials due to pain at the injection site. Report
> South San Francisco-based Proteolix has raised $79 million to fund its development of new drugs that target protein degradation pathways in cancer and autoimmune diseases. Report
> Shares of BioSante Pharmaceuticals surged 14 percent this morning after news hit that a mid-stage trial of its oral contraceptive--Pill-Plus--produced positive data with indications of increased sex drive among the women taking the pill. Report
> Pfizer and Ligand's osteoporosis drug Fablyn got the green light from an FDA advisory panel despite concerns that the drug could be linked to an increase rate of death. Report
And Finally... The extreme Arctic climate has given rise to a new era of bioprospecting in the frigid region. Report